Home/EAHP learning modules

EAHP learning modules

A number of modules for self-assessment are now available online via BMJ Learning. Aimed at hospital pharmacists and based on recordings of satellite events held at the annual European Association of Hospital Pharmacists (EAHP) Congress, they are free to access and accredited by the Accreditation Council for Pharmacy Education (ACPE). The events were financially supported by different external organisations but totally independent of industry involvement, with the faculty and the topics selected by the EAHP scientific committee. All users must complete a one-time registration on BMJ Learning and subsequently log in on every visit using their username and password to access modules and their CPD record. Accreditation is only valid for 2 years from the date of publication. Printable CPD certificates are available to users that achieve the minimum pass mark and complete a survey at the end of the course. 1.5-2 ACPE credits will be awarded, depending on the length of the course. eahp_logo


The Hospital Pharmacist’s role in antithrombotic stewardship Explains how to determine and manage the reversible risk factors for bleeding in patients taking Direct Oral Anticoagulants (DOACs), establish an antithrombotic stewardship programme to improve adherence to anticoagulant guidelines to minimize complications, and communicate this knowledge to other healthcare professionals. As DOACs are the first-line option for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) and the treatment of venous thromboembolism (VTE), it is essential that hospital pharmacists can balance the benefits and risks of these medications. Further information from EAHP

Biologicals and biosimilars

Hospital pharmacists making the difference Provides insight into how to implement and monitor biosimilars for oncologic therapy, tackles specific issues relating to their optimum use in the hospital arena, and explains how to assess the financial impact on healthcare systems. Hospital pharmacists can play a key role in the use of biosimilars for cancer care if they have a good understanding of their development, regulatory approval processes, and clinical utility. Further information from EAHP Biosimilars in colorectal cancer – what’s your gut feeling? Outlines the key concepts and facts which support biosimilar approval in the EU and explains how to implement biosimilars of monoclonal antibodies in the treatment of colorectal cancer. As new biosimilars for colorectal cancer are coming to the market, it is important for hospital pharmacists to be able to offer a scientific, unbiased perspective and act as key drivers in the implementation process in order to realise the significant opportunities for cost savings. Further information from EAHP

Management and leadership

Procurement, tendering, and decision making processes in the hospital setting Outlines the role of the hospital pharmacist in procurement and tendering, which are essential for managing medication costs at national, regional and local hospital levels. However, price is not the only consideration; value-based tenders include other aspects such as continuity of supply, patient safety, environmental aspects, quality-based factors and innovative characteristics.